Marit Rønning
Marit Rønning has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Anatoliy Reutskiy
Association of Family Doctors, Kaliningrad, Russia
2 shared publications - Arnoldas Jurgutis
Public Health Department, Faculty of Health Sciences, Klaipeda University, Lithuania
2 shared publications - Beatriz González López-Valcárcel
Department of Quantitative Methods in Economics and Management, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
2 shared publications - Bente Gahrn-Hansen
Department of Clinical Microbiology, Odense University Hospital, J.B.Winsløwsvej 21, 2, Odense C, 5000, Denmark
2 shared publications - Carl Llor
Research Unit for General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark
2 shared publications - Christos Lionis
Department of Social Medicine, School of Medicine, University of Crete, 70013 Heraklion, Greece
2 shared publications
Latest Publications
- Open Access
- 20 June 2011
- Published by Springer Nature in BMC Family Practice
- Vol. 12 (1) , 52
Health Alliance for prudent antibiotic prescribing in patients with respiratory tract infections (HAPPY AUDIT) -impact of a non-randomised multifaceted intervention programme
Excessive use of antibiotics is worldwide the most important reason for development of antimicrobial resistance. As antibiotic resistance may spread across borders, high prevalence countries may serve as a source of bacterial resistance for countries with a low prevalence. Therefore, bacterial resistance is an important issue with a potential serious impact on all countries. Initiatives have been taken to improve the quality of antibiotic prescribing in primary care, but only few studies have been designed to determine the effectiveness of multifaceted strategies across countries with different practice setting. The aim of this study was to evaluate the impact of a multifaceted intervention targeting general practitioners (GPs) and patients in six countries with different health organization and different prevalence of antibiotic resistance.
- 20 June 2011
- Published by Springer Nature in BMC Family Practice
- Vol. 12 (1) , 52
Open AccessHealth Alliance for prudent antibiotic prescribing in patients with respiratory tract infections (HAPPY AUDIT) -impact of a non-randomised multifaceted intervention programme
Excessive use of antibiotics is worldwide the most important reason for development of antimicrobial resistance. As antibiotic resistance may spread across borders, high prevalence countries may serve as a source of bacterial resistance for countries with a low prevalence. Therefore, bacterial resistance is an important issue with a potential serious impact on all countries. Initiatives have been taken to improve the quality of antibiotic prescribing in primary care, but only few studies have been designed to determine the effectiveness of multifaceted strategies across countries with different practice setting. The aim of this study was to evaluate the impact of a multifaceted intervention targeting general practitioners (GPs) and patients in six countries with different health organization and different prevalence of antibiotic resistance.
- Open Access
- 23 April 2010
- Published by Springer Nature in BMC Family Practice
- Vol. 11 (1) , 29
Health Alliance for Prudent Prescribing, Yield and Use of Antimicrobial Drugs in the Treatment of Respiratory Tract Infections (HAPPY AUDIT)
Excessive and inappropriate use of antibiotics is considered to be the most important reason for development of bacterial resistance to antibiotics. As antibiotic resistance may spread across borders, high prevalence countries may serve as a source of bacterial resistance for countries with a low prevalence. Therefore, bacterial resistance is an important issue with a potential serious impact on all countries.
- 23 April 2010
- Published by Springer Nature in BMC Family Practice
- Vol. 11 (1) , 29
Open AccessHealth Alliance for Prudent Prescribing, Yield and Use of Antimicrobial Drugs in the Treatment of Respiratory Tract Infections (HAPPY AUDIT)
Excessive and inappropriate use of antibiotics is considered to be the most important reason for development of bacterial resistance to antibiotics. As antibiotic resistance may spread across borders, high prevalence countries may serve as a source of bacterial resistance for countries with a low prevalence. Therefore, bacterial resistance is an important issue with a potential serious impact on all countries.
- 23 October 2008
- Vol. 128 (20) , 2324-9
[Antibiotic use in Norway].
Antibiotic use is a major cause of development and spread of resistant bacteria. Sensible antibiotic use should aim at decreasing total antibiotic use and replace broad-spectrum antibiotics with narrow-spectrum ones; pharmaceutical drug statistics are vital in this context. Data were collected from the wholesaler-based drug statistics (for the period 1974 - 2007) and from the Norwegian Prescription Database (2006). The ATC/DDD methodology is used in the drug statistics. Data are presented as number of users (prevalence), number of dispensed prescriptions, defined daily doses (DDD per 1 000 inhabitants per day) and in Norwegian kroner. Longitudinal trends show a relatively stable and high use of narrow-spectrum antibiotics, even though broad-spectrum antibiotic use is slightly increasing. Antibiotic use varies largely by age and sex. The highest prevalences are seen among small children (0 - 5 years), women in their twenties and in people over 70 years. Over 30 % of people in these groups receive at least one antibiotic per year. The therapy profile differs between the types of prescription issued. Neither the wholesaler statistics nor the Prescription Database contains information on diagnosis, making it difficult to monitor whether the Norwegian primary health service has a rational antibiotic therapy.
- 23 October 2008
- Vol. 128 (20) , 2324-9
[Antibiotic use in Norway].
Antibiotic use is a major cause of development and spread of resistant bacteria. Sensible antibiotic use should aim at decreasing total antibiotic use and replace broad-spectrum antibiotics with narrow-spectrum ones; pharmaceutical drug statistics are vital in this context. Data were collected from the wholesaler-based drug statistics (for the period 1974 - 2007) and from the Norwegian Prescription Database (2006). The ATC/DDD methodology is used in the drug statistics. Data are presented as number of users (prevalence), number of dispensed prescriptions, defined daily doses (DDD per 1 000 inhabitants per day) and in Norwegian kroner. Longitudinal trends show a relatively stable and high use of narrow-spectrum antibiotics, even though broad-spectrum antibiotic use is slightly increasing. Antibiotic use varies largely by age and sex. The highest prevalences are seen among small children (0 - 5 years), women in their twenties and in people over 70 years. Over 30 % of people in these groups receive at least one antibiotic per year. The therapy profile differs between the types of prescription issued. Neither the wholesaler statistics nor the Prescription Database contains information on diagnosis, making it difficult to monitor whether the Norwegian primary health service has a rational antibiotic therapy.
- 18 March 2003
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 58 (12) , 843-849
Problems in collecting comparable national drug use data in Europe: the example of antibacterials
To describe the methodological problems in collecting retrospectively comparable data on drug use and to compare the use of antibacterials in some European countries. A spreadsheet was distributed in 2000 through the European Drug Utilisation Research Group (EuroDURG) network, requesting 1994–1999 data on use of antibacterials for systemic use (ATC group J01), from ambulatory, hospital, or total care, aggregated at ATC 4th level, and presented in defined daily doses per 1000 inhabitants per day (in the 1999 ATC/DDD version or specified other version). The network was able to provide national utilization data for two or more years in the requested period from 16 countries (4 only from primary care, 3 both from primary care and total use, and 9 only total use data). The main methodological problems identified were: use of divergent ATC/DDD versions, divergent assignment of DDDs for combination products and the use of unofficial or national DDDs. It was possible to correct for the different ATC/DDD versions to some extent, except for the cephalosporin group (not included in the analysis), as the collection of data at the ATC 4th level precluded recalculation of DDDs. In the seven countries with primary care data the total J01 antibacterials use varied by a factor of 2.5 (Belgium 23.4 and The Netherlands 9.5 DDDs per 1000inhabitants per day). The use of J01A tetracyclines varied fourfold, and the use of J01C penicillins and J01F macrolides and lincosamides approximately threefold. Significant reduction over time was seen in J01A and an increase in J01F. In the scientific and regulatory community it is still difficult to perform a valid and comprehensive cross-national collection of utilization data on antibacterials. White spots on the European map persist for ambulatory care data, and data are missing for the hospital sector in most countries. For a thorough explanation of the considerable intercountry variability (especially in antibacterial subgroups and time trends analysis) a sustained and concerted effort is necessary to implement a validation process of the ATC/DDD use in the various countries and to adopt a common methodological approach to the collection of utilization data at the substance level (ATC 5th level).
- 18 March 2003
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 58 (12) , 843-849
Problems in collecting comparable national drug use data in Europe: the example of antibacterials
To describe the methodological problems in collecting retrospectively comparable data on drug use and to compare the use of antibacterials in some European countries. A spreadsheet was distributed in 2000 through the European Drug Utilisation Research Group (EuroDURG) network, requesting 1994–1999 data on use of antibacterials for systemic use (ATC group J01), from ambulatory, hospital, or total care, aggregated at ATC 4th level, and presented in defined daily doses per 1000 inhabitants per day (in the 1999 ATC/DDD version or specified other version). The network was able to provide national utilization data for two or more years in the requested period from 16 countries (4 only from primary care, 3 both from primary care and total use, and 9 only total use data). The main methodological problems identified were: use of divergent ATC/DDD versions, divergent assignment of DDDs for combination products and the use of unofficial or national DDDs. It was possible to correct for the different ATC/DDD versions to some extent, except for the cephalosporin group (not included in the analysis), as the collection of data at the ATC 4th level precluded recalculation of DDDs. In the seven countries with primary care data the total J01 antibacterials use varied by a factor of 2.5 (Belgium 23.4 and The Netherlands 9.5 DDDs per 1000inhabitants per day). The use of J01A tetracyclines varied fourfold, and the use of J01C penicillins and J01F macrolides and lincosamides approximately threefold. Significant reduction over time was seen in J01A and an increase in J01F. In the scientific and regulatory community it is still difficult to perform a valid and comprehensive cross-national collection of utilization data on antibacterials. White spots on the European map persist for ambulatory care data, and data are missing for the hospital sector in most countries. For a thorough explanation of the considerable intercountry variability (especially in antibacterial subgroups and time trends analysis) a sustained and concerted effort is necessary to implement a validation process of the ATC/DDD use in the various countries and to adopt a common methodological approach to the collection of utilization data at the substance level (ATC 5th level).